Questions about this study?
The HopeStage team will email you.
TerminatedNCT01127646
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
Medication studyAges 6–16Multiple countriesADHD
Understand this study
Who could participate?
Listed age limits: 6 years to 16 years.
- Listed locations
- Arnhem and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJune 2010
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 23
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Netherlands, Spain, Sweden
- Age range
- From 6 Years to 16 Years
- Official registry ID
- NCT01127646
- Official title
Show the full official title
Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)
Recruitment & locations
TerminatedArnhem, Netherlands · Capelle aan den IJssel, Netherlands · Maastricht, Netherlands
11 more locations
- Rotterdam, Netherlands
- Barcelona, Spain
- Donostia / San Sebastian, Spain
- Esplugues de Llobregat, Spain
- Palma de Mallorca, Spain
- Sabadell, Spain
- Gothenburg, Sweden
- Handen, Sweden
- Malmö, Sweden
- Stockholm, Sweden
- Uppsala, Sweden
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including Atomoxetine, Osmotic-release oral system methylphenidate and Placebo.
Who can participate?
Listed age limits: 6 years to 16 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A head-to-head randomized clinical trial of methylphenidate and lisdexamphetamine treatment for executive functions and global functioning in adults with ADHD
A multi-centre, randomized, parallel-group, single blind Phase II trial to evaluate the pharmacokinetics and PKPD relationship of trazodone after single and repeated oral doses in children from 2 t...